Capricor: A Detailed Examination Of Hope-3
Source: SeekingAlpha
2025-12-10 15:32:55 ET
Summary
Capricor is engaged in developing a human allogeneic cardiosphere-derived cell treatment for DMD patients. Management has discussed potentially obtaining both skeletal (neuromuscular) and cardiomyopathy indications....
Read the full article on Seeking Alpha
For further details see:
Capricor: A Detailed Examination Of Hope-3
Capricor Therapeutics Inc.
NASDAQ: CAPR
CAPR Trading
1.19% G/L:
$33.25 Last:
534,893 Volume:
$33.94 Open:
CAPR Latest News
March 12, 2026 04:01:00 pm
Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 12, 2026 09:00:00 am
Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy
March 10, 2026 09:25:00 am
Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA
CAPR Stock Data
$1,278,443,622
46,286,693
0.54%
28
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
